EQRx, Inc. (NASDAQ:EQRX) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET

Company Participants

Neil Swami - Head, Investor Relations

Melanie Nallicheri - President and Chief Executive Officer

Jami Rubin - Chief Financial Officer

Eric Hedrick - Chief Physician Executive

Conference Call Participants

Steve Scala - Cowen

Chris Schott - JPMorgan

Operator

Good morning and welcome to the EQRx Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded. I would now like to turn the call over to Neil Swami, Head of Investor Relations.

Neil Swami

Thank you, operator and good morning everyone. Earlier today, we issued a press release providing an overview of our third quarter 2022 financial results and our recent corporate progress. A copy of this release and presentation to accompany this call are available on the Investor Relations section of our website at investors.eqrx.com.

Joining me on the call this morning are Melanie Nallicheri, President and Chief Executive Officer; Jamie Rubin, Chief Financial Officer and Dr. Eric Hedrick, Chief Physician Executive.

Before we get started, I would like to remind everyone that some of the statements we make on this call and information presented in the slide deck include forward-looking statements, as outlined on Slide 2. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements. And EQRx disclaims any obligation to update such statements.

I will now turn the call over to Melanie.

Melanie Nallicheri

Thank you for taking the time today to join our third quarter call as we share significant updates about our late stage pipeline, our go-forward strategy in light of regulatory guidance, and our robust capital positioning and deployment now and in the coming quarters and years ahead.

To begin on Slide 4, over the last several weeks, we have had multiple discussions and written communications with the FDA around possible paths to approval for our most advanced medicines, aumolertinib and sugemalimab. We now have the feedback and clarity on the agency’s position to make decisions for both programs. For aumolertinib, we have a clear understanding of the FDA’s position on a path for potential U.S. approval. This incorporates advice from the FDA into the trial design to bring this potentially best-in-class compound to patients and provides commercial revenue in the U.S. as early as 2027, following our first expected UK and EU approvals and commercialization in the 2024 timeframe. Positive data for our recently initiated Phase 3b 3-arm study could support the use of aumolertinib in combination with chemotherapy as potential future standard of care, and possibly also as monotherapy in the U.S. population.